<DOC>
	<DOCNO>NCT02209597</DOCNO>
	<brief_summary>Determine bioequivalence brand generic bupropion extend release ( XL ) product ( generic product ) steady state patient major depressive disorder .</brief_summary>
	<brief_title>Bupropion Depression</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Inclusion Criteria Each subject must meet following criterion : 1 . Adult outpatient age 1875 year 2 . Currently daily bupropion HCl 300mg XL ( brand generic ) , minimum 4 month 3 . Major depressive disorder ( MDD ) , partial full remission least 4 month , confirm SCID . Spontaneous relapse depression unrelated medication change less likely 5 % chance per year remission maintain least 4 months.2 4 . Ability understand willingness comply study procedure , provide write informed consent Exclusion Criteria Subjects enrol follow criterion exist : 1 . Remission depression clearly attribute bupropion treatment 2 . Current severe side effect attributable bupropion 3 . Poor adherence bupropion treatment per patient self report history refill persistence 4 . History active seizure disorder , seizure treatment within past year 5 . History significant hepatic renal disease , base physician assessment 6 . Currently take drug natural product know influence cytochrome P450B6 ( CYP2B6 ) activity 7 . Currently take drug hepatitis C multiple sclerosis , due ability cause depression 8 . Dementia significant cognitive impairment , per diagnosis investigative team 's assessment 9 . Lifetime diagnosis schizophrenia , schizoaffective schizophreniform disorder , delusional disorder , current psychotic symptom diagnose SCID 10 . Abuse dependence alcohol substance within past 6 month determine SCID , confirm study physician interview 11 . Current suicidal ideation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>MDD</keyword>
	<keyword>bupropion XL</keyword>
	<keyword>Wellbutrin XL</keyword>
</DOC>